WO2021209747A1 - Ciment osseux - Google Patents

Ciment osseux Download PDF

Info

Publication number
WO2021209747A1
WO2021209747A1 PCT/GB2021/050891 GB2021050891W WO2021209747A1 WO 2021209747 A1 WO2021209747 A1 WO 2021209747A1 GB 2021050891 W GB2021050891 W GB 2021050891W WO 2021209747 A1 WO2021209747 A1 WO 2021209747A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid
storage stable
stable liquid
composition according
polymer particles
Prior art date
Application number
PCT/GB2021/050891
Other languages
English (en)
Inventor
Kadem Al-Lamee
William BALMER
Nial BULLETT
Original Assignee
Arterius Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arterius Limited filed Critical Arterius Limited
Publication of WO2021209747A1 publication Critical patent/WO2021209747A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0094—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing macromolecular fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0042—Materials resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0084—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • the present invention relates to two part hardenable compositions comprising a solid first part and a storage stable liquid second part which are operable to form a resorbable and injectable bone cement which hardens to a solid mass upon mixing of the parts together.
  • the present invention extends to the two part hardenable compositions for use in the treatment of human or animal bone, a method of producing a resorbable and injectable bone cement from the two part hardenable compositions, a solid bone cement produced from the two part hardenable compositions and a kit of parts comprising the two part hardenable compositions.
  • DRFs Distal radial fractures
  • DRF treatments commonly require complicated surgical procedures that can be painful for the patient and often have a risk of complications due to, for example, infections. This can lead to further surgical interventions being required.
  • Common DRF treatments include a wide range of therapies, which cover invasive as well as non-invasive treatments, such as, for example, plaster casts, pins, Kirchner wires, fillers, bone cements, externally fixated stabilising frame, plates and screws. Less invasive treatments are typically preferred in order to allow a rapid patient recovery and to reduce the risk of complications from invasive surgery.
  • An example of a less invasive treatment for DRFs involves the use of fillers and/or bone cements, which involves inserting material within the intramedullary canal of the bone to provide stiffness and stabilisation.
  • fillers and bone cements are made of non- resorbable materials and are commonly not injectable.
  • fillers are often reported as being too brittle once fully cured leading to a higher risk of further fractures in the same, or a similar, location.
  • a two part hardenable composition comprising a solid first part and a storage stable liquid second part, the solid first part and storage stable liquid part being operable to form a resorbable and injectable bone cement which hardens to a solid mass upon mixing of the parts together, the solid first part comprising:
  • each of the filler and the polymer particles, when present, have an average particle size of up to 200 pm and wherein the polymer particles, when present, have a weight-average molecular weight (Mw) of at least 10,000 Da; and
  • a method of producing a resorbable and injectable bone cement from a two part hardenable composition according to the first aspect of the present invention comprising the step of mixing the solid first part and the storage stable liquid second part.
  • a solid bone cement produced from mixing the solid first part and the storage stable liquid second part of the two part hardenable composition according to the first aspect of the present invention, wherein the solid bone cement is resorbable.
  • a fourth aspect of the present invention there is provided a two part hardenable composition according to the first aspect of the present invention for use in the treatment of human or animal bone.
  • kits of parts comprising the two part hardenable composition according to the first aspect of the present invention and a syringe or caulking gun.
  • Resorbable refers to materials that are capable of being completely degraded and/or eroded when installed in the body, and can be gradually resorbed, adsorbed and/or eliminated by the body. When used herein, this term can be used interchangeably with the terms “biodegradable”, “bioerodable” and “bioabsorbable”
  • “Injectable”, and like terms as used herein, refers to materials that are able to be injected and, in particular, which are able to be injected into a cavity using a syringe or caulking gun, for example.
  • the bone cements of the present invention are injectable upon and after mixing of the first and second parts and for the duration of the working time of said bone cements.
  • the bone cements are not injectable once said bone cements have hardened to a solid mass (i.e. after the setting time of said cements).
  • the two part hardenable compositions become a bone cement upon mixing of the first and second parts thereof together. Once the bone cement has hardened to a solid mass the bone cement may be referred to herein as a ‘hardened bone cement’.
  • the hardened bone cements of the present invention resorbable and injectable but they are also load bearing.
  • the hardened bone cements have sufficient mechanical strength to act in a load bearing capacity.
  • the use of the bone cements of the present invention comprising resorbable materials provides mechanical support for a relatively short period of time, such as for up to 20 weeks, such as for up to 18 weeks, such as for up to 16 weeks, such as for up to 14 weeks, such as for up to 12 weeks, or even for up to 10 weeks, before natural healing occurs. After this time, the bone cement may be resorbed by the body.
  • the solid first part comprises a filler and/or polymer particles.
  • the filler may be any suitable filler. Suitable fillers will be known to a person skilled in the art.
  • the filler may be organic or inorganic. Examples of suitable fillers include, but are not limited to, calcium phosphate, strontium-doped calcium phosphate compounds, bioglass, calcium carbonate, barium sulphate, hydroxyapatite, tetracalcium phosphate, octocalcium phosphate, monocalcium phosphate, heptacalcium phosphate, fluoroapatite, wollastonite, calcium pyrophosphate, oxyapatite, dicalcium phosphate, tricalcium phosphate such as, for example, a-, a’- or b-tricalcium phosphate, zirconium dioxide or combinations thereof.
  • the filler may comprise tricalcium phosphate, such as b-tricalcium phosphate, hydroxyapatite or combinations thereof.
  • the filler may comprise tricalcium phosphate. More suitably, the filler may comprise b-tricalcium phosphate.
  • the filler may be osteoinductive.
  • the filler when present, has an average particle size of up to 200 micron (pm).
  • the filler may have an average particle size of up to 175 pm, such as up to 150 pm, such as up to 145 pm, up to 140 pm, up to 130 pm, up to 125 pm, or even up to 100 pm.
  • the filler may have an average particle size of at least 0.25 pm, such as at least 0.5 pm, such as at least 1 pm, such as at least 5 pm, such as at least 10 pm, such as at least 15 pm, such as at least 20 pm, such as at least 30 pm, such as at least 40 pm, or even at least 50 pm.
  • the filler may have an average particle size from 0.25 to 200 pm, such as from 0.5 to 200 pm, such as from 1 to 200 pm, such as from 5 to 200 pm, such as from 10 to 200 pm, such as from 15 to 200 pm, such as from 20 to 200 pm, such as from 30 to 200 pm, such as from 40 to 200 pm, or even from 50 to 200 pm.
  • the filler may have an average particle size from 0.25 to 175 pm, such as from 0.5 to 175 pm, such as from 1 to 175 pm, such as from 5 to 175 pm, such as from 10 to 175 pm, such as from 15 to 175 pm, such as from 20 to 175 pm, such as from 30 to 175 pm, such as from 40 to 175 pm, or even from 50 to 175 pm.
  • the filler may have an average particle size from 0.25 to 150 pm, such as from 0.5 to 150 pm, such as from 1 to 150 pm, such as from 5 to 150 pm, such as from 10 to 150 pm, such as from 15 to 150 pm, such as from 20 to 150 pm, such as from 30 to 150 pm, such as from 40 to 150 pm, or even from 50 to 150 pm.
  • the filler may have an average particle size from 0.25 to 145 pm, such as from 0.5 to 145 pm, such as from 1 to 145 pm, such as from 5 to 145 pm, such as from 10 to 145 pm, such as from 15 to 145 pm, such as from 20 to 145 pm, such as from 30 to 145 pm, such as from 40 to 145 pm, or even from 50 to 145 pm.
  • the filler may have an average particle size from 0.25 to 140 pm, such as from 0.5 to 140 pm, such as from 1 to 140 pm, such as from 5 to 140 pm, such as from 10 to 140 pm, such as from 15 to 140 pm, such as from 20 to 140 pm, such as from 30 to 140 pm, such as from 40 to 140 pm, or even from 50 to 140 pm.
  • the filler may have an average particle size from 0.25 to 130 pm, such as from 0.5 to 130 pm, such as from 1 to 130 pm, such as from 5 to
  • the filler may have an average particle size from 0.25 to 125 pm, such as from 0.5 to 125 pm, such as from 1 to 125 pm, such as from 5 to 125 pm, such as from 10 to 125 pm, such as from 15 to 125 pm, such as from 20 to 125 pm, such as from 30 to 125 pm, such as from 40 to 125 pm, or even from 50 to 125 pm.
  • the filler may have an average particle size from 0.25 to 100 pm, such as from 0.5 to 100 pm, such as from 1 to 100 pm, such as from 5 to 100 pm, such as from 10 to 100 pm, such as from 15 to 100 pm, such as from 20 to 100 pm, such as from 30 to 100 pm, such as from 40 to 100 pm, or even from 50 to 100 pm.
  • the filler may have an average particle size from 50 to 200 pm.
  • the filler may have an average particle size from 50 to 150 pm.
  • the filler may have an average particle size from 50 to 145 pm.
  • the filler may have an average particle size up to 145 pm.
  • the filler may have an average particle size up to 100 pm.
  • the filler may have an average particle size from 50 to 145 pm.
  • the filler may have an average particle size from 50 to 100 pm.
  • the use of a filler having an average particle size of less than 200 pm means that the composition may be injectable, i.e. is able to be injected via a syringe or caulking gun, for example.
  • the solid first part preferably is substantially free or free of particles having an average particle size of greater than 200 pm.
  • the solid first part may comprise any suitable amount of filler, when present.
  • the solid first part may comprise up to 99.99 wt%, such as up to 99 wt%, such as up to 95 wt%, such as up to 90 wt%, such as up to 80 wt%, such as up to 70 wt%, such as up to 60 wt%, such as up to 50 wt%, such as up to 40 wt%, or even up to 30 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise at least 0.5 wt%, such as at least 1 wt%, such as at least 1 .5 wt%, such as at least 2 wt%, such as at least 2.5 wt%, such as at least 5 wt%, such as at least 7 wt%, such as at least 10 wt%, such as at least 15 wt%, or even at least 20 wt% filler based on the total solid weight of the solid first part.
  • at least 0.5 wt% such as at least 1 wt%, such as at least 1 .5 wt%, such as at least 2 wt%, such as at least 2.5 wt%, such as at least 5 wt%, such as at least 7 wt%, such as at least 10 wt%, such as at least 15 wt%, or even at least 20 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 99.99 wt%, such as from 1 to 99.99 wt%, such as from 1.5 to 99.99 wt%, such as from 2 to 99.99 wt%, such as from 2.5 to 99.99 wt%, such as from 5 to 99.99 wt%, such as from 7 to 99.99 wt%, such as from 10 to 99.99 wt%, such as from 15 to 99.99 wt%, or even from 20 to 99.99 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 99 wt%, such as from 1 to 99 wt%, such as from 1 .5 to 99 wt%, such as from 2 to 99 wt%, such as from 2.5 to 99 wt%, such as from 5 to 99 wt%, such as from 7 to 99 wt%, such as from 10 to 99 wt%, such as from 15 to 99 wt%, or even from 20 to 99 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 95 wt%, such as from 1 to 95 wt%, such as from 1 .5 to 95 wt%, such as from 2 to 95 wt%, such as from 2.5 to 95 wt%, such as from 5 to 95 wt%, such as from 7 to 95 wt%, such as from 10 to 95 wt%, such as from 15 to 95 wt%, or even from 20 to 95 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 90 wt%, such as from 1 to 90 wt%, such as from 1 .5 to 90 wt%, such as from 2 to 90 wt%, such as from 2.5 to 90 wt%, such as from 5 to 90 wt%, such as from 7 to 90 wt%, such as from 10 to 90 wt%, such as from 15 to 90 wt%, or even from 20 to 90 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 80 wt%, such as from 1 to 80 wt%, such as from 1 .5 to 80 wt%, such as from 2 to 80 wt%, such as from 2.5 to 80 wt%, such as from 5 to 80 wt%, such as from 7 to 80 wt%, such as from 10 to 80 wt%, such as from 15 to 80 wt%, or even from 20 to 80 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 70 wt%, such as from 1 to 70 wt%, such as from 1 .5 to 70 wt%, such as from 2 to 70 wt%, such as from 2.5 to 70 wt%, such as from 5 to 70 wt%, such as from 7 to 70 wt%, such as from 10 to 70 wt%, such as from 15 to 70 wt%, or even from 20 to 70 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 60 wt%, such as from 1 to 60 wt%, such as from 1 .5 to 60 wt%, such as from 2 to 60 wt%, such as from 2.5 to 60 wt%, such as from 5 to 60 wt%, such as from 7 to 60 wt%, such as from 10 to 60 wt%, such as from 15 to 60 wt%, or even from 20 to 60 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 50 wt%, such as from 1 to 50 wt%, such as from 1 .5 to 50 wt%, such as from 2 to 50 wt%, such as from 2.5 to 50 wt%, such as from 5 to 50 wt%, such as from 7 to 50 wt%, such as from 10 to 50 wt%, such as from 15 to 50 wt%, or even from 20 to 50 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 40 wt%, such as from 1 to 40 wt%, such as from 1 .5 to 40 wt%, such as from 2 to 40 wt%, such as from 2.5 to 40 wt%, such as from 5 to 40 wt%, such as from 7 to 40 wt%, such as from 10 to 40 wt%, such as from 15 to 40 wt%, or even from 20 to 40 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 30 wt%, such as from 1 to 30 wt%, such as from 1 .5 to 30 wt%, such as from 2 to 30 wt%, such as from 2.5 to 30 wt%, such as from 5 to 30 wt%, such as from 7 to 30 wt%, such as from 10 to 30 wt%, such as from 15 to 30 wt%, or even from 20 to 30 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 50 wt% filler based on the total solid weight of the solid first part.
  • the solid first part may comprise from 7 to 30 wt% filler based on the total solid weight of the solid first part.
  • the polymer particles may be any suitable polymer particles with the proviso that the polymer particles are resorbable. Suitable polymer particles will be known to a person skilled in the art. Suitably, the polymer particles may be operable to undergo hydrolysis, i.e. the polymer particles may be water soluble. Examples of suitable polymer particles include, but are not limited to, polylactides, polyglycolides, polycaprolactones, polyvinyl alcohol, Dextran, poly p-dioxanone, poly hydroxy butyrate and polyacrylates.
  • the polymer particles may comprise polyvinyl alcohol.
  • the polymer particles when present, have an average particle size of up to 200 microns (pm).
  • the polymer particles may have an average particle size of up to 175 pm, such as up to 150 pm, such as up to 145 pm, up to 140 pm, up to 130 pm, up to 125 pm, or even up to 100 pm.
  • the polymer particles may have an average particle size of at least 0.25 pm, such as at least 0.5 pm, such as at least 1 pm, such as at least 5 pm, such as at least 10 pm, such as at least 15 pm, such as at least 20 pm, such as at least 30 pm, such as at least 40 pm, or even at least 50 pm.
  • the polymer particles may have an average particle size from 0.25 to 200 pm, such as from 0.5 to 200 pm, such as from 1 to 200 pm, such as from 5 to 200 pm, such as from 10 to 200 pm, such as from 15 to 200 pm, such as from 20 to 200 pm, such as from 30 to 200 pm, such as from 40 to 200 pm, or even from 50 to 200 pm.
  • the polymer particles may have an average particle size from 0.25 to 175 pm, such as from 0.5 to 175 pm, such as from 1 to 175 pm, such as from 5 to 175 pm, such as from 10 to 175 pm, such as from 15 to 175 pm, such as from 20 to 175 pm, such as from 30 to 175 pm, such as from 40 to 175 pm, or even from 50 to 175 pm.
  • the polymer particles may have an average particle size from 0.25 to 150 pm, such as from 0.5 to 150 pm, such as from 1 to 150 pm, such as from 5 to 150 pm, such as from 10 to 150 pm, such as from 15 to 150 pm, such as from 20 to 150 pm, such as from 30 to 150 pm, such as from 40 to 150 pm, or even from 50 to 150 mhi.
  • the polymer particles may have an average particle size from 0.25 to 145 pm, such as from 0.5 to 145 pm, such as from 1 to 145 pm, such as from 5 to 145 pm, such as from 10 to 145 pm, such as from 15 to 145 pm, such as from 20 to 145 pm, such as from 30 to 145 pm, such as from 40 to 145 pm, or even from 50 to 145 pm.
  • the polymer particles may have an average particle size from 0.25 to 140 pm, such as from 0.5 to 140 pm, such as from 1 to 140 pm, such as from 5 to 140 pm, such as from 10 to 140 pm, such as from 15 to 140 pm, such as from 20 to 140 pm, such as from 30 to 140 pm, such as from 40 to 140 pm, or even from 50 to 140 pm.
  • the polymer particles may have an average particle size from 0.25 to 130 pm, such as from 0.5 to 130 pm, such as from 1 to 130 pm, such as from 5 to 130 pm, such as from 10 to 130 pm, such as from 15 to 130 pm, such as from 20 to 130 pm, such as from 30 to 130 pm, such as from 40 to 130 pm, or even from 50 to 130 pm.
  • the polymer particles may have an average particle size from 0.25 to 125 pm, such as from 0.5 to 125 pm, such as from 1 to 125 pm, such as from 5 to 125 pm, such as from 10 to 125 pm, such as from 15 to 125 pm, such as from 20 to 125 pm, such as from 30 to 125 pm, such as from 40 to 125 pm, or even from 50 to 125 pm.
  • the polymer particles may have an average particle size from 0.25 to 100 pm, such as from 0.5 to 100 pm, such as from 1 to 100 pm, such as from 5 to 100 pm, such as from 10 to 100 pm, such as from 15 to 100 pm, such as from 20 to 100 pm, such as from 30 to 100 pm, such as from 40 to 100 pm, or even from 50 to 100 pm.
  • the polymer particles may have an average particle size from 50 to 200 pm.
  • the polymer particles may have an average particle size from 50 to 150 pm.
  • the polymer particles may have an average particle size from 50 to 145 pm.
  • the polymer particles may have an average particle size up to 145 pm.
  • the polymer particles may have an average particle size up to 100 pm.
  • the polymer particles may have an average particle size from 50 to 145 pm.
  • the polymer particles may have an average particle size from 50 to 100 pm.
  • the use of polymer particles having an average particle size of less than 200 pm means that the composition may be injectable, i.e. is able to be injected via a syringe or caulking gun, for example.
  • the polymer particles may have an Mw of at least 20,000 Da, such as at least 30,000 Da, such as at least 40,000 Da, such as at least 50,000 Da, such as at least 60,000 Da, such as at least 70,000 Da, such as at least 80,000 Da, such as at least 90,000 Da, or even at least 100,000 Da.
  • the polymer particles may have an Mw of up to 750,000 Da, such as up to 500,000 Da, or even up to 250,000 Da.
  • the polymer particles may have an Mw from 10,000 to 750,000 Da, such as from 20,000 to 750,000 Da, such as from 30,000 to 750,000 Da, such as from 40,000 to 750,000 Da, such as from 50,000 to 750,000 Da, such as from 60,000 to 750,000 Da, such as from 70,000 to 750,000 Da, such as from 80,000 to 750,000 Da, such as from 90,000 to 750,000 Da, or even from 100,000 to 750,000 Da.
  • the polymer particles may have an Mw from 10,000 to 500,000 Da, such as from 20,000 to 500,000 Da, such as from 30,000 to 500,000 Da, such as from 40,000 to 500,000 Da, such as from 50,000 to 500,000 Da, such as from 60,000 to 500,000 Da, such as from 70,000 to 500,000 Da, such as from 80,000 to 500,000 Da, such as from 90,000 to 500,000 Da, or even from 100,000 to 500,000 Da.
  • the polymer particles may have an Mw from 10,000 to 250,000 Da, such as from 20,000 to 250,000 Da, such as from 30,000 to 250,000 Da, such as from 40,000 to 250,000 Da, such as from 50,000 to 250,000 Da, such as from 60,000 to 250,000 Da, such as from 70,000 to 250,000 Da, such as from 80,000 to 250,000 Da, such as from 90,000 to 250,000 Da, or even from 100,000 to 250,000 Da.
  • the polymer particles may have an Mw of at least 10,000 Da.
  • the polymer particles may have an Mw of at least 50,000 Da.
  • the weight average molecular weight (Mw) may be determined by gel permeation chromatography (GPC).
  • the solid first part comprises an initiator.
  • the initiator is suitably able to initiate free-radical polymerisation of the monomer component of the storage stable liquid second part.
  • the initiator may be any suitable initiator. Suitable initiators will be known to a person skilled in the art. Examples of suitable initiators include, but are not limited to: peroxides such as, for example, t-butyl hydroperoxide, dicumylperoxide, di-tert-butyl peroxide, benzoyl peroxide, tert- amylhydroperoxide, di-(2-ethylhexylperoxydicarbonate and lauroyl peroxide; persulphates such as, for example, potassium persulphate, sodium persulphate and ammonium persulphate; azo initiators such as, for example, 4,4’-azobis(4-cyanovaleric acid); and combinations thereof.
  • peroxides such as, for example, t-butyl hydroperoxide, dicumylperoxide, di-tert-butyl peroxide, benzoyl peroxide, tert- amylhydroperoxide, di-(
  • the initiator may comprise benzoyl peroxide.
  • the initiator is present in the solid first part an amount of 0.01 to 15 wt% based on the total weight of the solid first part.
  • the solid first part may comprise at least 0.05 wt%, such as at least 0.1 wt%, such as at least 0.15 wt%, such as at least 0.25 wt%, such as at least 0.5 wt%, such as at least 0.7 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise up to 14 wt%, such as up to 13 wt%, such as up to 12 wt%, such as up to 11 wt%, such as up to 10 wt%, such as up to 9 wt%, up to 8 wt%, up to 7 wt%, up to 6 wt%, up to 5 wt%, up to 4 wt% , up to 3 wt%, up to 2 wt% or even up to 1 wt% initiator based on the total solid weight of the solid first part.
  • up to 14 wt% such as up to 13 wt%, such as up to 12 wt%, such as up to 11 wt%, such as up to 10 wt%, such as up to 9 wt%, up to 8 wt%, up to 7 wt%, up to 6 wt%, up to 5 wt%, up to 4 wt% , up to 3 wt%, up to
  • the solid first part may comprise from 0.01 to 15 wt%, such as from 0.01 to 14 wt%, such as from 0.01 to 13 wt%, such as from 0.01 to 12 wt%, such as from 0.01 to 11 wt%, such as from 0.01 to 10 wt%, such as from 0.01 to 9 wt%, from 0.01 to 8 wt%, from 0.01 to 7 wt%, from 0.01 to 6 wt%, from 0.01 to 5 wt%, from 0.01 to 4 wt%, from 0.01 to 3 wt%, from 0.01 to 2 wt%, from 0.01 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.05 to 15 wt%, such as from 0.05 to 14 wt%, such as from 0.05 to 13 wt%, such as from 0.05 to 12 wt%, such as from 0.05 to 11 wt%, such as from 0.05 to 10 wt%, such as from 0.05 to 9 wt%, from 0.05 to 8 wt%, from 0.05 to 7 wt%, from 0.05 to 6 wt%, from 0.05 to 5 wt%, from 0.05 to 4 wt%, from 0.05 to 3 wt%, from 0.05 to 2 wt%, from 0.05 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.1 to 15 wt%, such as from 0.1 to 14 wt%, such as from 0.1 to 13 wt%, such as from 0.1 to 12 wt%, such as from 0.1 to 11 wt%, such as from 0.1 to 10 wt%, such as from 0.1 to 9 wt%, from 0.1 to 8 wt%, from 0.1 to 7 wt%, from 0.1 to 6 wt%, from 0.1 to 5 wt%, from 0.1 to 4 wt%, from 0.1 to 3 wt%, from 0.1 to 2 wt%, from 0.1 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.15 to 15 wt%, such as from 0.15 to 14 wt%, such as from 0.15 to 13 wt%, such as from 0.15 to 12 wt%, such as from 0.15 to 11 wt%, such as from 0.15 to
  • 10 wt% such as from 0.15 to 9 wt%, from 0.15 to 8 wt%, from 0.15 to 7 wt%, from 0.15 to 6 wt%, from 0.15 to 5 wt%, from 0.15 to 4 wt%, from 0.15 to 3 wt%, from 0.15 to 2 wt%, from 0.15 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.25 to 15 wt%, such as from 0.25 to 14 wt%, such as from 0.25 to 13 wt%, such as from 0.25 to 12 wt%, such as from 0.25 to 11 wt%, such as from 0.25 to 10 wt%, such as from 0.25 to 9 wt%, from 0.25 to 8 wt%, from 0.25 to 7 wt%, from 0.25 to 6 wt%, from 0.25 to 5 wt%, from 0.25 to 4 wt%, from 0.25 to 3 wt%, from 0.25 to 2 wt%, from 0.25 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 15 wt%, such as from 0.5 to 14 wt%, such as from 0.5 to 13 wt%, such as from 0.5 to 12 wt%, such as from 0.25 to 1 wt% initiator based on the total
  • 11 wt% such as from 0.5 to 10 wt%, such as from 0.5 to 9 wt%, from 0.5 to 8 wt%, from 0.5 to 7 wt%, from 0.5 to 6 wt%, from 0.5 to 5 wt%, from 0.5 to 4 wt%, from 0.5 to 3 wt%, from 0.5 to 2 wt%, from 0.5 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.7 to 15 wt%, such as from 0.7 to 14 wt%, such as from 0.7 to 13 wt%, such as from 0.7 to 12 wt%, such as from 0.7 to 11 wt%, such as from 0.7 to 10 wt%, such as from 0.7 to 9 wt%, from 0.7 to 8 wt%, from 0.7 to 7 wt%, from 0.7 to 6 wt%, from 0.7 to 5 wt%, from 0.7 to 4 wt%, from 0.7 to 3 wt%, from 0.7 to 2 wt%, from 0.7 to 1 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.01 to 10 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.25 to 10 wt% initiator based on the total solid weight of the solid first part.
  • the solid first part may comprise from 0.5 to 10 wt% initiator based on the total solid weight of the solid first part.
  • the use of the initiator in an amount of 0.01 to 15 wt% based on the total weight of the solid first part results in a hardened bone cement having increased working times than would typically be expected when using more than 15 wt% of the initiator based on the total weight of the solid first part.
  • the use of the initiator in an amount of 0.01 to 15 wt% based on the total weight of the solid first part results in a hardened bone cement having improved mechanical properties than would typically be expected when using more than 15 wt% of the initiator based on the total weight of the solid first part.
  • the initiator is suitably present at a level which will affect polymerisation of the monomer component that is at least 90% polymerisation, such as at least 93% polymerisaton, or even at least 95% polymerisation.
  • the storage stable liquid second part comprises a monomer component, wherein the monomer component is operable to undergo free radical polymerisation in the presence of the initiator to form a polymer upon mixing of the parts together.
  • the monomer component suitably comprises one or more monomer(s).
  • the monomer component may comprise any suitable monomer(s) with the proviso that the polymer formed from the free radical polymerisation of the monomer component is resorbable.
  • the monomer(s) may have ethylenic unsaturation.
  • the monomer(s) may comprise one or more ethylenically unsaturated monomers(s). It will be appreciated by a person skilled in the art that ethylenically unsaturated monomers may suitably be chosen such that they are able to undergo free radical polymerisation.
  • the monomers may comprise one or more hydrolysable group(s), such as, for example, ester groups.
  • the polymer formed from the free-radical polymerisation of the monomer component may comprise one or more ester group-containing side chains.
  • the use of one or more monomer(s) having one or more hydrolysable group(s), such as ester group(s) means that the resultant polymer, formed from the free-radical polymerisation of said monomer(s), are resorbable.
  • Suitable monomers will be known to a person skilled in the art.
  • the monomers are operable to form polymers that are able to undergo hydrolysis, i.e. the monomers are operable to form polymers that are water soluble.
  • suitable monomers include, but are not limited to, polyethylene glycol methyl ether acrylate, polyethylene glycol methyl ether methacrylate, N- vinyl pyrrolidone, polyhexamethylene adipate, polyethylene glycol diacrylate, polypropylene fumarate, polypropylene glycol fumarate, acrylic acid, methacrylic acid, N-vinylformamide and combinations thereof.
  • the monomer component may comprise N-vinyl pyrrolidone.
  • the monomer component may be present in the storage stable liquid second part in any suitable amount.
  • the storage stable liquid first part may comprise at least 2.5 wt%, such as at least 3 wt%, such as at least 4 wt%, or even at least 5 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise up to 25 wt%, such as up to 20 wt%, such as up to 15 wt%, or even up to 10 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 25 wt%, such as from 3 to 25 wt%, such as from 4 to 25 wt%, or even from 5 to 25 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 20 wt%, such as from 3 to 20 wt%, such as from 4 to 20 wt%, or even from 5 to 20 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 15 wt%, such as from 3 to 15 wt%, such as from 4 to 15 wt%, or even from 5 to 15 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 10 wt%, such as from 3 to 10 wt%, such as from 4 to 10 wt%, or even from 5 to 10 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 20 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 5 to 20 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 10 to 15 wt% of the monomer component based on the total weight of the storage stable liquid second part.
  • the monomer component and the initiator are located in separate parts of the said two part hardenable composition so that the liquid second part containing the monomer component is storage stable to polymerization.
  • the storage stable liquid second part comprises 0.5 to 50 wt% of a crosslinker material based on the total weight of the storage stable liquid second part.
  • the use of the crosslinker material may give the final cured bone cement sufficient stiffness for the desired application.
  • the crosslinker material may comprise any suitable crosslinker material. Suitable crosslinkers will be known to a person skilled in the art.
  • the crosslinker material may be at least di-functional, i.e. have at least two (2) functional groups that are able to participate in a crosslinking reaction.
  • the crosslinker material may be di-, tri-, or tetra-functional, for example.
  • the crosslinker material may comprise one of more di-functional crosslinker material(s) and/or one or more tetra-functional crosslinker material(s).
  • di-functional crosslinker materials include, but are not limited to, glyoxal, polyethylene glycol diacrylate, polyethylene glycol diglycidyl ether, ethylene glycol dimethacrylate, ethylene glycol diacrylate, di(trimethylolpropane), di(triethylolpropane), di(trimethylolethane), di(triethylolethane) and combinations thereof.
  • the di-functional crosslinker material may comprise polyethylene glycol diacrylate, ethylene glycol dimethacrylate, ethylene glycol diacrylate and combinations thereof.
  • the di-functional crosslinker material may comprise ethylene glycol dimethacrylate and/or di(trimethylolpropane). More suitably, the di-functional crosslinker material may comprise ethylene glycol dimethacrylate.
  • tetra-functional crosslinker materials include, but are not limited to, di(trimethylolpropane) tetraacrylate, di(triethylolpropane) tetraacrylate, di(trimethylolethane) tetraacrylate, di(triethylolethane) tetraacrylate, 4-Arm PEG-acrylate and combinations thereof.
  • the tetra-functional crosslinker material may comprise di(trimethylolpropane) tetraacrylate.
  • the crosslinker material may alternatively or additionally comprise one or more multifunctional crosslinker material(s), whereby where by ‘multi-functional’ is meant a crosslinker material which is other than di- or tetra-functional.
  • suitable multi-functional crosslinker materials include, but are not limited to, 8-Arm PEG-acrylate.
  • the storage stable liquid second part may comprise one or more di-functional crosslinker material and one or more tetra-functional crosslinker material.
  • the storage stable liquid second part may comprise ethylene glycol dimethacrylate and/or di(trimethylolpropane) tetraacrylate. More suitably, the storage stable liquid second part may comprise ethylene glycol dimethacrylate and di(trimethylolpropane) tetraacrylate.
  • the crosslinker material may be resorbable.
  • the crosslinker material may comprise one or more hydrolysable group(s), such as ester group(s).
  • the use of one or more crosslinker material(s) having one or more hydrolysable groups, such as ester group(s) means that said crosslinker material(s) are resorbable.
  • the crosslinker material may be present in the storage stable liquid second part in any suitable amount.
  • the storage stable liquid second part may comprise at least 2.5 wt%, such as at least 5 wt%, such as at least 7.5 wt%, such as at least 10 wt%, or even at least 12.5 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise up to 25 wt%, such as up to 20 wt%, or even up to 15 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 25 wt%, such as from 5 to 25 wt%, such as from 7.5 to 25 wt%, such as from 10 to 25 wt%, or even from 12.5 to 25 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 20 wt%, such as from 5 to 20 wt%, such as from 7.5 to 20 wt%, such as from 10 to 20 wt%, or even from 12.5 to 20 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 15 wt%, such as from 5 to 15 wt%, such as from 7.5 to 15 wt%, such as from 10 to 15 wt%, or even from 12.5 to 15 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 2.5 to 25 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 5 to 20 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the storage stable liquid second part may comprise from 10 to 15 wt% crosslinker material based on the total weight of the storage stable liquid second part.
  • the amount of crosslinker material may vary depending on the functionality of said crosslinker material. For example, if a difunctional crosslinker material is used, more of said di-functional crosslinker material may be required compared to when, for example, a tetra-functional crosslinker material is used. Conversely, if a tetra-functional crosslinker material is used, less of said tetra-functional crosslinker material may be required compared to when, for example, a di-functional crosslinker material is used.
  • the storage stable liquid second part may further comprise an activator.
  • an activator in the context of the present invention is a compound that acts to lower the activation energy of the initiators) as defined herein.
  • the storage stable liquid second part may further comprise any suitable activator.
  • suitable activators will be known to a person skilled in the art. Examples of suitable activators include, but are not limited to, N,N- dimethyl-p-toluidine (DMPT), 4-(dimethylamino) phenethyl alcohol, N,N-bis (2-hydroxyethyl)-p- toluidine, N,N-bis (2-hydroxyethyl)-p-xylidine and combinations thereof.
  • an activator depends upon the final application. Where “cold-cure” is necessary, for example in bone cements, an activator is typically necessary. However, for some applications the use of heat in “heat-cure” systems is also possible. In heat-cure systems an activator is typically not necessary.
  • the activator when present, is suitably present at a level that will effectively activate the polymerisation reaction in the presence of initiator.
  • the storage stable liquid second part may further comprise water and/or other solvents) as additional liquid components.
  • the water and/or other solvent(s), when present, may suitably be sufficient to provide a liquid carrier for the other components present in the storage stable liquid second part such as, the monomer component, crosslinker material and, optionally, activator.
  • the storage stable liquid second part may further comprise an inhibitor.
  • the storage stable liquid second part may comprise any suitable inhibitor. Suitable inhibitors will be known to a person skilled in the art. Examples of suitable inhibitors include, but are not limited to, hydroquinone (HQ), methyl hydroquinone (MeHQ), 2,6-di-tertiary-butyl-4-methoxyphenol (Topanol O), 2,4-dimethyl-6-tertiary-butyl phenol (Topanol A) and combinations thereof.
  • the inhibitor may suitably be present to prevent the monomer component from spontaneously polymerising.
  • a suitable inhibitor is 60ppm of hydroquinone to ensure long shelf life at room temperature.
  • the two part hardenable composition may comprise a radiopacifying agent.
  • Radiopacifying means the ability to render a material more distinguishable from surrounding material when subjected to X-rays.
  • the two part hardenable composition may comprise any suitable radiopacifying agent.
  • suitable radiopacifying agents will be known to a person skilled in the art.
  • suitable radiopacifying agents include, but are not limited to, zirconium dioxide, bismuth oxides, iodine compounds such as iohexal, iodixanol, strontium carbonate, powdered gold, powdered platinum, powdered iridium, powdered, powdered tantalum, powdered rhodium, powdered tungsten, barium sulphate and combinations thereof.
  • the radiopacifying agent may comprise barium sulphate.
  • the radio pacifying agent when present, may be present in the solid first part and/or the storage stable liquid second part.
  • the radiopacifying agent may be present in the solid first part.
  • the solid first part may further comprise a radiopacifying agent.
  • the radiopacifying agent may be present in the solid first part in any suitable amount.
  • the solid first part may comprise at least 5 wt%, such as at least 6 wt%, such as at least 7 wt%, such as at least 8 wt%, or even at least 9 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise up to 30 wt%, such as up to 25 wt%, such as up to 20 wt%, such as up to 15 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 30 wt%, such as from 6 to 30 wt%, such as from 7 to 30 wt%, such as from 8 to 30 wt%, such as from 9 to 30 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 25 wt%, such as from 6 to 25 wt%, such as from 7 to 25 wt%, such as from 8 to 25 wt%, such as from 9 to 25 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 20 wt%, such as from 6 to 20 wt%, such as from 7 to 20 wt%, such as from 8 to 20 wt%, such as from 9 to 20 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 15 wt%, such as from 6 to 15 wt%, such as from 7 to 15 wt%, such as from 8 to 15 wt%, such as from 9 to 15 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 30 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 5 to 20 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the solid first part may comprise from 10 to 20 wt% radiopacifying agent based on the total solid weight of the solid first part.
  • the radiopacifying agent when present, is suitably distributed throughout the polymer matrix of said hardened bone cement.
  • the solid first part and storage stable liquid part are operable to form a bone cement which hardens to a solid mass upon mixing of the parts together.
  • a method of producing a bone cement from a two part hardenable composition according to the first aspect of the present invention comprising the step of mixing the solid first part and the storage stable liquid second part.
  • the bone cements may have any suitable working time.
  • the working time is the time during which the viscosity of the bone cement is such that it may be injected and/or manipulated by an operator.
  • the bone cements may have a working time from 3 to 20 minutes, such as from 4 to 15 minutes, such as from 4 to 10 minutes, such as from 4 to 7 minutes, or even from 4 to 5 minutes. It will be appreciated by a person skilled in the art that the working time is the time during which the bone cement is injectable. After the working time, i.e. once the bone cement has hardened to a solid mass, the bone cements are no longer injectable.
  • the time in which is takes the bone cement to harden to a solid mass is known as the setting time.
  • the bone cements may have any suitable setting time.
  • the bone cements may have a setting time from 5 to 25 minutes, such as from 6 to 20 minutes, such as from 7 to 15 minutes, such as from 7 to 10 minutes, such as from 7 to 8 minutes, or even 7 minutes.
  • the bone cements of the present invention have a working time that is at least sufficient to allow an operator to inject and/or manipulate the cement in the desired fashion.
  • the mixing of the solid first part and storage stable liquid second part may be carried out by any suitable technique.
  • the mixing of the solid first part and storage stable liquid second part may be performed by a manual mixing process or by the use of an optionally adapted syringe or caulking gun.
  • a general procedure for mixing the solid first part and the storage stable liquid second part of the hardenable composition of the invention is described as follows: before mixing, the two parts are equilibrated for a suitable period, such as 1 hour or more at a temperature of 5 to 40°C, such as 10 to 35°C, or even 15 to 30°C.
  • the solid first part is mixed with a suitable amount of storage stable liquid second part according to the ratios defined herein. Mixing is then carried out at the equilibrated temperature for at least 5 seconds, such as at least 20 seconds, or even at least 30 seconds.
  • the material may be injected within a cavity, such as a bone cavity, and allowed to exotherm and harden.
  • the bone cement is suitably injected into a cavity, such as a bone cavity, within the working time of the bone cement (as hereinbefore described).
  • the solid first part and storage stable liquid second part may be mixed at the equilibrated temperature in a static mixer connected to twin compartments of a syringe or caulking gun, for example.
  • a static mixer connected to twin compartments of a syringe or caulking gun, for example.
  • the material may be injected into a cavity, such as a bone cavity, and allowed to exotherm and harden.
  • the mixing of the solid first part and storage stable liquid second part may be performed by the use of an optionally adapted syringe or caulking gun.
  • the solid first part and storage stable liquid second part may be mixed together at any suitable ratio.
  • the solid first part and storage stable liquid second part may be mixed at a ratio of 2:1 to 1 :2 by mass, such as at a ratio of 2:1 to 1 :1 by mass, or even at a ratio of 1 :1 by mass.
  • the filler and/or polymer particles are wetted with monomer, solvated and begin to dissolve.
  • the initiator interacts with activator, if present, to produce free radicals that react with the monomer component and initiate room temperature addition polymerisation of the monomer component.
  • the mixture starts out at a relatively low viscosity and progresses to a stiffer and stiffer system that eventually hardens completely to a hardened bone cement.
  • a solid bone cement produced from mixing the solid first part and the storage stable liquid second part of the two part hardenable composition according to the first aspect of the present invention, wherein the solid bone cement is resorbable.
  • Suitable features of the third aspect of the present invention are as defined herein in relation to the first and/or second aspects of the present invention.
  • the hardened bone cement may have any suitable flexural strength.
  • the hardened bone cement may have a flexural strength of at least 15 mega Pascals (MPa), such as at least 20 MPa, or even at least 25 MPa.
  • MPa mega Pascals
  • the hardened bone cement may have any suitable flexural modulus.
  • the hardened bone cement may have a flexural modulus of at least 200 mega Pascals (MPa), such as at least 400 MPa, such as at least 500 MPa, such as at least 1 ,000 MPa, such as at least 1 ,200 MPa, or even at least 1 ,400 MPa.
  • the hardened bone cement may have any suitable ‘strain to break’.
  • the hardened bone cement may have a strain to break of up to 10%, such as up to 7.5%, or even up to 5%.
  • the composition is biocompatible and in particular hardens to a solid cement that is biocompatible in situ.
  • the composition of the invention finds particularly advantageous utility as a medical implant material such as a bone cement.
  • the two part hardenable composition may suitably be a bone cement composition.
  • a fourth aspect of the present invention there is provided a two part hardenable composition according to the first aspect of the present invention for use in the treatment of human or animal bone.
  • a fifth aspect of the present invention there is provided a two part hardenable composition according to the first aspect of the present invention for use in the repair or partial repair of human or animal bone.
  • Suitable features of the fourth and/or fifth aspects of the present invention are as defined herein in relation to the first, second and/or third aspects of the present invention.
  • kits of parts comprising the two part hardenable composition according to the first aspect of the present invention, a syringe or caulking gun and, optionally, a balloon.
  • Suitable features of the fifth aspect of the present invention are as defined herein in relation to the first, second, third, fourth and/or fifth aspects of the present invention.
  • the syringe and/or caulking gun may be any suitable syringe and/or caulking gun. Suitable syringes and/or caulking guns will be known to a person skilled in the art.
  • the balloon when present, may be any suitable balloon.
  • Such balloons can easily be implanted within a cavity, such as a bone cavity, using an appropriate delivery system and, together with the bone cement, can provide sufficient support.
  • Suitable balloons will be known to a person skilled in the art.
  • the balloon may be commercially available.
  • the bone cements of the present invention may suitably be injected into the balloon in situ.
  • the use of a balloon enables the bone cement to be removed from the body, such as a human or animal body, if necessary.
  • the balloon itself may be resorbable or non-resorbable.
  • liquid herein does not require definition because it is well understood by the person skilled in the art. However, for the avoidance of doubt it also includes a flowable material having a liquid carrier such as a slurry, suspension, emulsion or paste that is thus susceptible of delivery through a syringe or caulking gun outlet by the application of pressure.
  • a liquid carrier such as a slurry, suspension, emulsion or paste that is thus susceptible of delivery through a syringe or caulking gun outlet by the application of pressure.
  • the term liquid is applicable to the material or composition at least between 5 and 35°C, more typically, between 5 and 30°C.
  • solid part means a non-liquid or non-gaseous part and is generally a free flowing dry particulate material usually made up of one or a mixture of powder(s) and not including a liquid carrier.
  • storage stable is meant that the monomer or liquid does not polymerize under normally acceptable storage conditions of temperature and time i.e. between 5 and 30°C and 1 to 250 days, such as 15 to 25°C and 1 to 170 days.
  • any numerical range recited herein is intended to include all sub-ranges subsumed therein. [141] Singular encompasses plural and vice versa.
  • a filler for example, although reference is made herein to "a” filler, “a” crosslinker material, “an” initiator, and the like, one or more of each of these and any other components can be used.
  • polymer refers to oligomers and both homopolymers and copolymers, and the prefix “poly” refers to two or more. Including, for example and like terms means including for example but not limited to.
  • the term "and/or,” when used in a list of two or more items, means that any one of the listed items can be employed by itself or any combination of two or more of the listed items can be employed. For example, if a list is described as comprising group A, B, and/or C, the list can comprise A alone; B alone; C alone; A and B in combination; A and C in combination, B and C in combination; or A, B, and C in combination.
  • the term "and combinations thereof when used in a list of two or more items means that any one of the listed items can be employed by itself or any combination of two or more of the listed items can be employed.
  • the list can comprise A alone; B alone; C alone; A and B in combination; A and C in combination, B and C in combination; or A, B, and C in combination.
  • Comparative example 1 is a semi-resorbable cement which was prepared according to the formulation in Table 2.
  • the polymer formed from the monomer component, methyl methacrylate, of comparative example 1 is not able to undergo hydrolysis such that it is not resorbable.
  • Comparative Example 2 is Versabond (RTM), a non-resorbable commercially available cement from Smith and Nephew, containing in 19.87 g methyl methacrylate (stabilized with hydroquinone) and 0.13 g N,N-dimethyl-p-toluidine in Part (A) and 18.0 g methyl methacrylate- methacrylate copolymer, 20.0 g methyl methacrylate homopolymer, 0.5 g benzoyl peroxide (hydrous 75%), 3.8 g zirconium dioxide, in Part (B).
  • RTM Versabond
  • RTM Versabond
  • Flexural strength the flexural strength of the cements was measured according to the three point bend test according to ISO-5833 with the exception that a cylindrical sample is used instead of a sample having a rectangular cross section.
  • the flexural strength of the cement of Example 6 was also measured according to the four point bend test according to ISO-5833 with the exception that a cylindrical sample is used instead of a sample having a rectangular cross section.
  • the cylindrical sample in each example had a diameter of 8.5 mm and a length of 40 mm.
  • Flexural modulus the flexural modulus was measured according to the three point bend test according to ISO 5833 with the exception that a cylindrical sample is used instead of a sample having a rectangular cross section.
  • the flexural modulus of the cement of Example 6 was also measured according to the four point bend test according to ISO-5833 with the exception that a cylindrical sample is used instead of a sample having a rectangular cross section.
  • the cylindrical sample in each example had a diameter of 8.5 mm and a length of 40 mm.
  • strain at break was measured according to the three point bend test according to ISO 5833 with the exception that a cylindrical sample is used instead of a sample having a rectangular cross section.
  • the flexural strength of the cement of Example 6 was also measured according to the four point bend test according to ISO-5833 with the exception that a cylindrical sample is used instead of a sample having a rectangular cross section.
  • the cylindrical sample in each example had a diameter of 8.5 mm and a length of 40 mm. Table 3 - Results including three point bend test results

Abstract

L'invention concerne une composition durcissable en deux parties comprenant une première partie solide et une seconde partie liquide stable au stockage. Les parties sont utilisables pour former un ciment osseux résorbable et injectable qui durcit en une masse solide lors du mélange des parties ensemble. La première partie solide comprend une charge et/ou des particules polymères, chacune de la charge et des particules polymères, lorsqu'elles sont présentes, ont une taille moyenne de particule allant jusqu'à 200 µm et les particules polymères, lorsqu'elles sont présentes, ont un poids moléculaire moyen en poids (Mw) d'au moins 10 000 Da ; et de 0,01 à 15 % en poids d'un initiateur sur la base du poids total de la première partie solide. La seconde partie liquide stable au stockage comprend un composant monomère, le composant monomère pouvant être utilisé pour subir une polymérisation radicalaire en présence de l'initiateur pour former un polymère lors du mélange des parties ensemble ; et de 0,5 à 50 % en poids d'un matériau de réticulation sur la base du poids total de la partie liquide stable au stockage. Chacune des particules polymères, lorsqu'elles sont présentes, et le polymère formé à partir de la polymérisation radicalaire du composant monomère sont résorbables. L'invention s'étend à une composition durcissable en deux parties destinée à être utilisée dans le traitement d'un os humain ou animal et un kit de pièces comprenant la composition durcissable en deux parties et une seringue ou un pistolet à calfeutrer.
PCT/GB2021/050891 2020-04-15 2021-04-14 Ciment osseux WO2021209747A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2005488.8 2020-04-15
GB2005488.8A GB2594243A (en) 2020-04-15 2020-04-15 A bone cement

Publications (1)

Publication Number Publication Date
WO2021209747A1 true WO2021209747A1 (fr) 2021-10-21

Family

ID=70847992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2021/050891 WO2021209747A1 (fr) 2020-04-15 2021-04-14 Ciment osseux

Country Status (2)

Country Link
GB (1) GB2594243A (fr)
WO (1) WO2021209747A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US20030180344A1 (en) * 2002-02-05 2003-09-25 Cambridge Scientific, Inc. Bioresorbable osteoconductive compositions for bone regeneration
US20160184190A1 (en) * 2013-08-02 2016-06-30 Ucl Business Plc Formulations and materials with cationic polymers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486232B1 (en) * 1997-04-18 2002-11-26 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for internal fixation devices and bone cements
US6124373A (en) * 1998-04-10 2000-09-26 Wm. Marsh Rice University Bone replacement compound comprising poly(polypropylene fumarate)
WO2000063268A1 (fr) * 1999-04-16 2000-10-26 Wm. Marsh Rice University Poly(propylene fumarate) reticule avec du poly(ethylene glycol)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US20030180344A1 (en) * 2002-02-05 2003-09-25 Cambridge Scientific, Inc. Bioresorbable osteoconductive compositions for bone regeneration
US20160184190A1 (en) * 2013-08-02 2016-06-30 Ucl Business Plc Formulations and materials with cationic polymers

Also Published As

Publication number Publication date
GB202005488D0 (en) 2020-05-27
GB2594243A (en) 2021-10-27

Similar Documents

Publication Publication Date Title
US9107951B2 (en) Calcium particle-embedded, snap-to-dough, high-viscosity bone cement
US9089625B2 (en) Bone cement composition and method of making the same
US7968616B2 (en) Bone cement composition and method
AU2006274588B2 (en) Bone cement and methods of use thereof
EP1367960B1 (fr) Ciment osseux
US9642932B2 (en) Bone cement and methods of use thereof
AU2006268058B2 (en) Bone cement composition
WO1990003193A1 (fr) Ciment pour implants osseux
US20040157954A1 (en) Bone cement composition
WO2021209747A1 (fr) Ciment osseux
US9393346B2 (en) Polymer cements used for fixing prostheses, for bone repair and for vertebroplasty, and obtained from liquid single-phase formulations
CN111867640B (zh) 硬组织修补用组合物及硬组织修补用套装
AU2013204295B2 (en) Bone cement and methods of use thereof
AU2012258391B2 (en) Bone cement and methods of use thereof
JP2021141993A (ja) 硬組織補修用組成物及び硬組織補修用キット
Başgörenay Preparation and characterization of hydroxyapatite containing acrylic bone cements
CONTENT The study aim was development of composite bone cements with lower monomer content, viscosity and modulus but a higher conversion and strength than the commercial composite CortossTM
AU2011226788A1 (en) Bone Cement and Methods of Use Thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21721582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21721582

Country of ref document: EP

Kind code of ref document: A1